Kenvue IncNYSE: KVUE
Consumer Staples · Personal Care Products
$17.46
-0.40%
Vol: 9.4M
Research Digest
Friday, May 1, 2026
Kenvue announced CFO transition with Heather Howlett as interim CFO, while Kimberly-Clark acquisition approval progresses with shareholder votes showing approximately 99% support.
Kenvue reported Q4 2025 sales growth of 3.2% YoY with organic sales up 1.2%, outperforming Street estimates. The pending $48.7 billion Kimberly-Clark acquisition, approved by ~99% of Kenvue shareholders and ~96% of Kimberly-Clark shareholders, is expected to close in H2 2026. Leadership transitions include Heather Howlett joining as interim CFO effective May 12, 2026. Analyst price targets have been cut recently, with Citi lowering to $19 from $20 and Barclays cutting to $18 from $19.
Previous Market Intelligence
13 daysApr 30Kenvue advancing toward Kimberly-Clark $48.7B acquisition close in H2 2026; quarterly dividend declaredNeutral▶
Kenvue Inc. is advancing toward completion of its $48.7 billion acquisition by Kimberly-Clark, with stockholders voting to approve the merger and related proposals. The transaction is set to close in the second half of 2026 subject to regulatory approval and customary closing conditions. Kenvue's Board declared a quarterly cash dividend of $0.2075 per share, payable May 27, 2026 to shareholders of record on May 13. The company reported 2025 revenue of $15.12 billion (down 2.14% YoY) and earnings of $1.47 billion (up 42.72%). Kirk Perry serves as interim CEO following prior leadership changes. Analyst outlook remains mixed with 11 analysts averaging a Buy rating and a 12-month price target of $19.45, up 10.89% from current levels. Recent analyst cuts from Citi and Barclays suggest caution.
Apr 29Kenvue declares quarterly dividend of $0.2075; third consecutive annual raise; acquisition by Kimberly-Clark pending in H2 2026Neutral▶
Kenvue Inc. declared quarterly dividend of $0.2075 per share (ex-date May 13, payable May 27), representing third consecutive annual increase and 4.73% yield. World's largest pure-play consumer health company reported FY2025 sales up 3.2% (beating Street estimate of 0.4%) with organic sales up 1.2%. Kenvue brands include Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena and Tylenol. Acquisition by Kimberly-Clark set to close in H2 2026. Q1 2026 earnings due May 7. Citi lowered target to $19 from $20; Barclays to $18 from $19. Stock down 23.8% over 52 weeks.
Apr 16Kenvue CFO Amit Banati to resign effective May 12; Heather Howlett named interim CFO as Kimberly-Clark acquisition progresses toward H2 2026 close.Neutral▶
Kenvue announced CFO transition with Amit Banati resigning effective May 12, 2026, replaced by interim CFO Heather Howlett who receives $125,000 monthly stipend. Kimberly-Clark deal targeting H2 2026 close with combined company operating four segments totaling $31.6B annual sales. Stock closed April 15 at $17.30, down 0.46%. Q4 2025 results showed net sales +3.2%, organic +1.2%, though full-year 2025 sales declined 2.1%.
Apr 15Kenvue shareholders approved Kimberly-Clarks $48.7 billion acquisition; deal expected to close in H2 2026.Positive▶
Kenvue shareholders approved Kimberly-Clarks $48.7 billion acquisition deal on April 9, 2026, clearing a major milestone toward completion in H2 2026. The merger creates a $32 billion global health and wellness leader. Q4 2025 results showed net sales up 3.2% and EPS of $0.27 beating $0.22 estimate.
Apr 14Kenvue maintains focus on dermatology innovation amid Kimberly-Clark acquisition process.Neutral▶
No significant overnight updates. Kenvue continues execution under the Kimberly-Clark acquisition announced in 2025, expected to close in H2 2026. Company showcased new dermatology products at the American Academy of Dermatology meeting. RBC Capital maintained Hold rating.
Apr 13Kenvue stock declined as pending Kimberly-Clark acquisition at $48.7B remains on track with mixed analyst sentiment.Negative▶
Kenvue traded down 1.38% at $17.30 amid the ongoing $48.7B acquisition by Kimberly-Clark expected to close in H2 2026. Q1 earnings beat expectations with EPS of $0.27 vs $0.22 estimated. Analysts remain cautious given competitive pressures and potential litigation risks. Median analyst price target at $19.0 with six analysts providing guidance.
Apr 10Kenvue shareholders overwhelmingly approve Kimberly-Clark acquisition; transaction expected to close in H2 2026.Positive▶
Kenvue shareholders approved the proposed Kimberly-Clark acquisition with ~99% of votes adopting the merger agreement and ~77% of outstanding shares voting in favor. Transaction expected to close in H2 2026. Kenvue reported strong Q4 2025 results: adjusted EPS $0.27 (beat consensus $0.22), revenue $3.78B (beat $3.68B).
Apr 9Kimberly-Clark acquisition of Kenvue approved by shareholders with 99% vote on $48.7B dealNeutral▶
Kenvue shareholders voted to approve Kimberly-Clark's acquisition with approximately 99% of votes adopting the merger agreement and about 77% of outstanding Kenvue shares voting in favor. The transaction values Kenvue at approximately $48.7 billion in enterprise value and is expected to close in the second half of 2026. Kenvue reported 2025 net sales of $15.1 billion with a 16% operating margin. The company provides differentiated brands including Tylenol, Neutrogena, Listerine, and Johnson's.
Apr 8Kimberly-Clark acquisition of Kenvue overwhelmingly approved; closing expected H2 2026Positive▶
Kenvue shareholders voted 99% in favor of Kimberly-Clark's $48.7B acquisition with Kimberly-Clark shareholders voting 96% approval (announced November 2025). Q4 2025 net sales grew 3.2% to $3.78B with adjusted EPS of $0.27, beating estimates. Transaction closing expected second half 2026 pending regulatory approval. Stock stabilized near deal implied value (~$19). Rep. Kevin Hern sold shares April 7, reflecting insider activity amid pending transaction and pre-merger restructuring efforts.
Apr 7Kenvue under pending acquisition by Kimberly-Clark, expected close H2 2026.Neutral▶
Kenvue pending acquisition by Kimberly-Clark closing H2 2026. Kirk Perry permanent CEO. Stock $17.25, $33.14B mcap, 4.8% forward yield. -8.42% 30d. Tylenol litigation continues after Feb 26 ruling. RBC Hold Feb 23. Q1 2026 May 13.
Apr 6Kenvue Awaits Kimberly-Clark Merger ClosingNeutral▶
Kenvue Inc. shareholders overwhelmingly approved the proposed $20+ billion merger with Kimberly-Clark, with approximately 99% of votes adopting the merger agreement. The transaction is expected to close in the second half of 2026, subject to regulatory approvals. In Q4 2025, Kenvue reported net sales growth of 3.2% with organic sales up 1.2%. Full-year 2025 diluted EPS was $0.76 and adjusted diluted EPS was $1.08. A Texas judge rejected Kenvue's bid to dismiss a lawsuit by Attorney General Ken Paxton alleging concealment of autism and other risks related to Tylenol use during pregnancy. Stock closed at $17.20, down slightly in after-hours. According to 11 analysts, average rating is "Buy" with 12-month price target of $19.73, representing 15.04% upside.
Apr 3No significant overnight updates for Kenvue; Kimberly-Clark acquisition pending close H2 2026 at $21.01 per share.Neutral▶
No material news in the last 48 hours. Kenvue closed at $17.38 on April 1. Key development is the pending Kimberly-Clark acquisition offering $3.50 cash plus 0.14625 KMB shares ($21.01 total per share). Deal expected to close H2 2026 subject to approvals. Stock trading at significant discount to deal value, indicating acquisition completion concerns.
Apr 2No significant overnight updates; Kenvue trades at $17.38 as Kimberly-Clark acquisition moves toward H2 2026 close; Buy consensus at $19.73.Neutral▶
Kenvue closed April 1 at $17.38 (up 0.81% daily). Company is advancing through Kimberly-Clark acquisition process (announced ~$48.7B deal) targeting closure in H2 2026. Stock down 5% recently with analysts adjusting targets. Analyst consensus: Buy (11 analysts) with 12-month price target $19.73 (15.04% upside). No material overnight news from past 24 hours; market focused on deal closure timeline.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| PGPROCTER | $147.58 | +0.33% | +3.0% | 20.7x | 0.40 | $342.5B |
| KVUEKENVUE | $17.46 | -0.40% | +1.3% | 14.6x | 0.57 | $33.7B |
| ELESTEE | $79.10 | +3.11% | +8.2% | 25.4x | 1.25 | $27.7B |
| WMTWALMART | $131.84 | -0.07% | +4.0% | 40.2x | 0.66 | $1.05T |
| COSTCOSTCO | $1,012.70 | -0.18% | -0.4% | 45.1x | 0.98 | $450.1B |
| KOCOCA | $78.69 | -0.10% | +2.0% | 22.7x | 0.36 | $338.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.